Last reviewed · How we verify
Fresh frozen plasma transfusion
Fresh frozen plasma transfusion replaces deficient clotting factors and other plasma proteins to restore hemostatic function in patients with coagulopathy or massive bleeding.
Fresh frozen plasma transfusion replaces deficient clotting factors and other plasma proteins to restore hemostatic function in patients with coagulopathy or massive bleeding. Used for Massive transfusion / acute hemorrhage with coagulopathy, Multiple clotting factor deficiency, Reversal of warfarin in emergency settings.
At a glance
| Generic name | Fresh frozen plasma transfusion |
|---|---|
| Sponsor | Rutgers, The State University of New Jersey |
| Drug class | Blood product / Plasma derivative |
| Modality | Biologic |
| Therapeutic area | Hematology / Transfusion Medicine |
| Phase | Phase 3 |
Mechanism of action
FFP is a blood product containing all vitamin K-dependent clotting factors (II, V, VII, X), fibrinogen, and other plasma proteins. It is used to correct multiple factor deficiencies when specific factor replacement is unavailable or impractical. FFP restores coagulation cascade function and improves hemostasis in acute bleeding or surgical settings.
Approved indications
- Massive transfusion / acute hemorrhage with coagulopathy
- Multiple clotting factor deficiency
- Reversal of warfarin in emergency settings
- Thrombotic thrombocytopenic purpura (TTP) plasma exchange
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Transfusion-associated circulatory overload (TACO)
- Infection transmission risk
- Febrile non-hemolytic transfusion reaction
Key clinical trials
- Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura (NA)
- Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment. (NA)
- Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients (PHASE3)
- Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis (PHASE1)
- A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (PHASE2, PHASE3)
- Transfusion Surveillance in Anaesthesia
- Preventive Strategies for Early and Late Complications of Leptospirosis (PHASE2)
- Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: